Introduction {#ss1}
============

In April 2009, a novel triple reassortant influenza H1N1 virus (nH1N1), with a unique genomic profile combining seasonal H3N2 and H1N1 subtypes and a swine‐origin H1N1 subtype, was identified in association with human respiratory illness in Mexico and California.[^1^](#b1){ref-type="ref"}, [^2^](#b2){ref-type="ref"} The rapid global spread of nH1N1 led the World Health Organization to declare an influenza pandemic on June 11, 2009.[^3^](#b3){ref-type="ref"} Despite its novelty and widespread, the 2009 nH1N1 pandemic is characterized by relatively mild clinical outcomes in a vast majority of individuals.[^4^](#b4){ref-type="ref"}, [^5^](#b5){ref-type="ref"} Furthermore, the incidence of severe cases caused by nH1N1 appeared to be significantly lower than that caused by the human seasonal influenza viruses.[^6^](#b6){ref-type="ref"} While pre‐existing immunity because of prior exposure to similar viral strains may provide an explanation for the reduced severity of nH1N1 infection,[^7^](#b7){ref-type="ref"}, [^8^](#b8){ref-type="ref"}, [^9^](#b9){ref-type="ref"}, [^10^](#b10){ref-type="ref"}, [^11^](#b11){ref-type="ref"} the extent to which different components of the host immune system (i.e., cellular and humoral responses) affect disease outcomes remains controversial.[^12^](#b12){ref-type="ref"}

As a major surface protein of influenza viruses, hemagglutinin (HA) plays a pivotal role in viral infection by binding to surface receptors on respiratory epithelial cells.[^13^](#b13){ref-type="ref"}, [^14^](#b14){ref-type="ref"} The HA gene consists of two subunits HA1 and HA2, produced by enzymatic cleavage of a precursor HA molecule (HA0).[^15^](#b15){ref-type="ref"}, [^16^](#b16){ref-type="ref"}, [^17^](#b17){ref-type="ref"} The HA1 subunit contains both highly conserved and variable regions. The HA1 gene being a major target for neutralizing antibodies, it is not surprising that it accumulates mutations in response to this strong immunological pressure.[^18^](#b18){ref-type="ref"}, [^19^](#b19){ref-type="ref"} The HA2 gene, in contrast to HA1, is highly conserved[^20^](#b20){ref-type="ref"}, [^21^](#b21){ref-type="ref"} and usually does not appear to be target for neutralizing antibodies mainly owing to limitations of its exposure on the viral surface.[^21^](#b21){ref-type="ref"}, [^22^](#b22){ref-type="ref"}, [^23^](#b23){ref-type="ref"}, [^24^](#b24){ref-type="ref"} Nevertheless, it has been shown to induce strong CD4+ T‐cell responses.[^25^](#b25){ref-type="ref"}

Previous studies have demonstrated a critical role of the CD4+ T‐cells in the host's defense against influenza virus infection, in part by regulating the production of neutralizing antibodies from B‐lymphocytes. Moreover, many T‐cell epitopes are conserved across influenza virus strains, making available memory T‐cells that could contribute to protective immunity.[^26^](#b26){ref-type="ref"} In the context of influenza nH1N1 infection, recent serological studies have shown the presence of some level of cross‐reactive antibody titers in groups of individuals older than 60 years of age, but no protection for children and younger adults.[^27^](#b27){ref-type="ref"}, [^28^](#b28){ref-type="ref"} Moreover, the presence of cross‐reactive T‐cells among influenza strains has been shown, even in the absence of cross‐reactive antibodies.[^8^](#b8){ref-type="ref"}, [^11^](#b11){ref-type="ref"}, [^29^](#b29){ref-type="ref"}, [^30^](#b30){ref-type="ref"}

Understanding the nature of pre‐existing immune responses in populations when a novel influenza virus strain emerges is critical for the formulation of effective, efficient public health responses to epidemics.[^31^](#b31){ref-type="ref"}, [^32^](#b32){ref-type="ref"} However, for reasons of practicality and cost, most large‐scale efforts to rapidly evaluate population immune responses to emerging infectious diseases emphasize humoral rather than cellular immune responses. Given the importance of CD4+ T‐cells in regulating B‐cell and cytotoxic T‐lymphocyte (CTL) responses,[^33^](#b33){ref-type="ref"} we sought to investigate the degree of conserved CD4+ T‐cell epitopes in the HA gene to determine whether prior exposure to seasonal influenza A strains would be expected to provide benefits against nH1N1 strains.

Results {#ss2}
=======

Analysis of MHC class II predicted conserved epitopes {#ss3}
-----------------------------------------------------

Amino acid sequences of HA1 and HA2 regions of sH1N1 and vH1N1 strains (as described in [Materials and Methods](#ss6){ref-type="sec"} section) shared, respectively, 72% and 91·8% identity with that of nH1N1. We focused our analysis on identifying epitopes recognized by CD4+ T‐cells in the context of major histocompatibility complex (MHC) II. Epitope analysis identified 15 amino acids length peptide sequences binding to various MHC II alleles specific to human leukocyte antigen (HLA)‐DRB1 (supplementary information, Tables S2--S6). A total of 147 strong binders were predicted with the MHC II allele (DRB1\*0101) for vH1N1 and the 2008 sH1N1, whereas 124 strong binders were identified for nH1N1 strains with the same MHC II allele. Next‐predicted MHC allele was DRB1\*0701 with 54 strong binders in vH1N1 and the sH1N1 2008, and 51 strong binders in nH1N1. There are no binders identified with the following alleles: DRB1\*0301, DRB1\*0801, DRB1\*1101, and DRB1\*1301. We considered conserved regions at the level of the 9‐mer sequence 'frame' that fits into the MHC binding groove and found a total of 119 CD4+ MHC II epitopes to be 100% conserved among sH1N1, vH1N1, and nH1N1 strains. Of these 119 conserved epitopes, 21 were from the HA1 region and 98 from the HA2 region. CD4+ MHC II epitopes found in HA1 and HA2 regions were predicted to bind with multiple MHC alleles (i.e., promiscuous MHC II epitopes; [Table 1](#t1){ref-type="table-wrap"}). Consistent with previous observations,[^7^](#b7){ref-type="ref"} some of the HA1‐ and HA2‐predicted MHC II binders were also identified to be MHC class I epitopes. A number of the MHC II epitopes from nH1N1 strain binding to MHC class I alleles are A\*0101, A\*0301 (LSSVSSFER); A\*0201 (WTYNAELLV, YNAELLVLL, VTVTHSVNL, YQILAIYST); A\*2402 (IYSTVASSL, FWMCSNGSL); and B\*0702 (IPSIQSRGL). Notably, all of these eight epitopes were 100% conserved with the vaccine strain A/Brisbane/59/2007 H1N1 used in the 2008--2009 season, and also recommended for the 2009--2010 season.[^34^](#b34){ref-type="ref"} Out of 18 MHC class II epitopes predicted in our analysis, eight were shown to be 100% conserved with MHC class I epitopes as reported by De Groot *et al.* [^10^](#b10){ref-type="ref"} ([Table 2](#t2){ref-type="table-wrap"}). Some of these epitopes were also found in the list of B‐cell, T‐cell class I and T‐cell class II epitopes that are deposited in the Immune Epitope Database (IEDB).[^11^](#b11){ref-type="ref"} Cross‐reactivity between sH1N1 and nH1N1 was estimated to be 52%, by dividing the conserved epitopes by the total common binders as described in [Table 3](#t3){ref-type="table-wrap"}.

###### 

 88·8% (8/9)--100% (9/9) conserved peptides of sH1N1 and nH1N1 with reference to Major Histocompatibility Complex class II alleles

  HA region        DRB1\*0101                                                                        DRB1\*0401   DRB1\*0404   DRB1\*0701            DRB1\*1501
  ---------------- --------------------------------------------------------------------------------- ------------ ------------ --------------------- -------------------------------
  HA1 (1--327)     YHANNSTDT LREQLSSVS LRNIPSIQS IPSIQSRGL FGAIAGFIE                                 LRNIPSIQS    LRNIPSIQS    VTVTHSVNL LSSVSSFER   IPSIQSRGL
  HA2 (328--535)   IEKMNTQFT WTYNAELLV YNAELLVLL LVLLENERT YQILAIYST YSTVASSLV FWMCSNGSL YEKVKSQLK   LVLLENERT    LVLLENERT    IYSTVASSL YSTVASSLV   LVLLENERT LAIYSTVAS LVLLVSLGA

###### 

 CD4+ and CD8+ T‐cell predicted conserved epitopes of nH1N1, which are, respectively, 88·8% (8/9) and 100% (9/9) conserved with the seasonal influenza type H1N1. Mutations in epitopes are highlighted in red

  HA region                           Epitope category   Source                                   
  ----------------------------------- ------------------ ---------------------------------------- ----------------------------------------
  HA1 conserved epitopes (1--327)     LSSVSSFER          LSSVSSFER                                This study[^10^](#b10){ref-type="ref"}
  VTVTHSVNL                           VTVTHSVNL          This study[^10^](#b10){ref-type="ref"}   
  IPSIQSRGL                           IPSIQSRGL          This study[^10^](#b10){ref-type="ref"}   
  LRNIPSIQS                                              This study                               
  LREQLSSVS                                              This study                               
  FGAIAGFIE                                              This study                               
  YHANNSTDT                                              This study                               
  HA2 conserved epitopes (328--535)   IEKMNTQFT                                                   This study
  WTYNAELLV                           WTYNAELLV          This study[^10^](#b10){ref-type="ref"}   
  YNAELLVLL                           YNAELLVLL          This study[^10^](#b10){ref-type="ref"}   
  LVLLENERT                                              This study                               
  YEKVKSQLK                                              This study                               
  YQILAIYST                           YQILAIYST          This study[^10^](#b10){ref-type="ref"}   
  LAIYSTVAS                                              This study                               
  IYSTVASSL                           IYSTVASSL          This study[^10^](#b10){ref-type="ref"}   
  YSTVASSLV                                              This study                               
  LVLLVSLGA                                              This study                               
  FWMCSNGSL                           FWMCSNGSL          This study[^10^](#b10){ref-type="ref"}   

MHC, Major Histocompatibility Complex.

###### 

 Estimation of cross‐reactivity based on the conserved binders versus common binders. The probability of cross‐immunity is the ratio of conserved strong binders to the total common strong binders (represented in percentage)

                                                                       MHC          Conserved strong binders   Total common strong binders   CD4+ T‐cell cross‐reactivity
  -------------------------------------------------------------------- ------------ -------------------------- ----------------------------- ------------------------------
  nH1N1 (2009) versus vH1N1 (1999, 2006, 2007) and sH1N1(1977--2008)   DRB1\*0101   58                         119                           48.3%
  DRB1\*0301                                                           0            0                          0                             
  DRB1\*0401                                                           10           16                         62%                           
  DRB1\*0404                                                           8            19                         42%                           
  DRB1\*0701                                                           16           37                         43%                           
  DRB1\*0801                                                           0            0                          0                             
  DRB1\*1101                                                           0            9                          0                             
  DRB1\*1301                                                           0            0                          0                             
  DRB1\*1302                                                           0            0                          0                             
  DRB1\*1501                                                           27           27                         100                           
  Cumulative                                                                        119                        227                           52%

Correlation in epitope conservancy {#ss4}
----------------------------------

To ensure that analyzed epitope data in this study correspond to those of the 2009 pandemic nH1N1 strain, we used the conserved epitopes (CD4+ T‐cell) predicted from recent sH1N1 (2008) and vH1N1 (2007) strains of influenza. Mapping these conserved epitopes on the sequences submitted during the period of 1968--2009 for H3N2, 1977--2009 for sH1N1 and 2009 for nH1N1 strains, we found that the conservancy among all the individual epitopes ranges from 33·3% to 100% ([Table 4](#t4){ref-type="table-wrap"}). The number of predicted sH1N1‐conserved epitopes in nH1N1 remained the same. [Figure 1A--C](#f1){ref-type="fig"} represents mean conservancy for each epitope over years between strain groups (nH1N1 versus sH1N1, nH1N1 versus H3N2, and sH1N1 versus H3N2). Mutated epitopes within years were also considered. This figure shows highly conserved epitopes dispersed in the HA region since the emergence of strains. Statistically significant correlation was found between sH1N1 versus nH1N1 epitope conservancy (*r* = 0·51, *P* value = 0·03), whereas other groups H3N2 versus nH1N1 and sH1N1 versus H3N2 showed no significant correlation. This analysis supports our estimation of 52% cross‐reactivity based on the conservancy.

###### 

 Conservancy ratios of predicted epitopes in sH1N1, H3N2, and nH1N1

  Epitopes   Immune response   Within sH1N1 strains (1977--2009)   Within nH1N1 strains (2009)   Within H3N2 strains (1968--2009)   
  ---------- ----------------- ----------------------------------- ----------------------------- ---------------------------------- -------------
   7--15     YHANNSTDT         CD4+                                100%                          100%                               33·3--44·4%
  24--32     VTVTHSVNL         CD4+ &CD8+                          100%                          88·8--100%                         33·3--44·4%
  101--109   LREQLSSVS         CD4+                                88·8--100%                    100%                               33·3--44·4%
  105--113   LSSVSSFER         CD4+ & CD8+                         100%                          88·8--100%                         44·4%
  317--325   LRNIPSIQS         CD4+                                88·8--100%                    88·8--100%                         44·4--66·6%
  320--328   IPSIQSRGL         CD4+ & CD8+                         88·8--100%                    88·8--100%                         44·4--66·6%
  329--337   FGAIAGFIE         CD4+                                100%                          100%                               88·8--100%
  382--390   IEKMNTQFT         CD4+                                100%                          100%                               44·4--55·5%
  418--426   WTYNAELLV         CD4+ & CD8+                         100%                          100%                               66·6--88·8%
  420--428   YNAELLVLL         CD4+ & CD8+                         100%                          88·8--100%                         66·6--88·8%
  423--433   LVLLENERT         CD4+                                100%                          100%                               55·5--66·6%
  445--452   YEKVKSQLK         CD4+                                100%                          88·8--100%                         33·3--44·4%
  510--518   YQILAIYST         CD4+ & CD8+                         100%                          100%                               33·3--55·5%
  514--522   LAIYSTVAS         CD4+                                100%                          100%                               44·4%
  515--523   IYSTVASSL         CD4+ & CD8+                         88·8--100%                    100%                               44·4--55·5%
  516--524   YSTVASSLV         CD4+                                100%                          100%                               44·4--55·5%
  523--531   LVLLVSLGA         CD4+                                100%                          88·8--100%                         44·4--55·5%
  534--542   FWMCSNGSL         CD4+ & CD8+                         100%                          100%                               33·3--44·4%

![ Comparative epitope conservancy: (A) nH1N1 and sH1N1. (B) nH1N1 and H3N2, and (C) sH1N1 and H3N2. Note: sH1N1 (1985, 1989, 1990, 1992, 1993, 1994, 1997, 1998, 1999, and 2004) sequences and H3N2 (1979, 1981, 1982, 1984, 1987, 1989, 1991, and 1992) sequences are not available in National Center for Biotechnology Information Influenza database. Hence, they are not represented in these figures. Mutated epitopes within the same year are represented as year followed by a, b, c. Accession numbers are given in Table S7 of the supplementary information.](IRV-4-249-g001){#f1}

[Figure 2](#f2){ref-type="fig"} highlights CD4+ and CD8+ specific as well as overlapping epitopes in the nH1N1‐HA protein sequence. The predicted epitopes -- YHANNSTDT (7--15), VTVTHSVNL (24--32), LREQLSSVS (101--109), and LSSVSSFER (105--113) -- were found to be highly conserved (percentage of conservancy, 88·8--100%) in the sH1N1 (1977--2009) and nH1N1 (2009) strains. These epitopes overlap with experimentally verified neutralising antibody‐binding sites,[^35^](#b35){ref-type="ref"}, [^36^](#b36){ref-type="ref"}, [^37^](#b37){ref-type="ref"}, [^38^](#b38){ref-type="ref"} as represented in [Figure 2](#f2){ref-type="fig"}.

![ Predicted epitopes and functional related sites represented on the novel H1N1‐HA protein sequence.](IRV-4-249-g002){#f2}

Discussion {#ss5}
==========

The 2009 H1N1 pandemic appears (with reference to case--fatality rates) to have been the mildest influenza pandemic on record,[^4^](#b4){ref-type="ref"} although severity has varied markedly across geographies and communities.[^39^](#b39){ref-type="ref"} This lack of severity has resulted in a degree of retrospective criticism of the response to the 2009 pandemic as overly aggressive.[^40^](#b40){ref-type="ref"}, [^41^](#b41){ref-type="ref"} Older adults at highest risk of complications of severe influenza appear to have had a high degree of immunity to infection, although given that this has been a feature noted in prior pandemics, it is unlikely that this observation is sufficient to explain between‐pandemic variability in severity.[^42^](#b42){ref-type="ref"}, [^43^](#b43){ref-type="ref"}, [^44^](#b44){ref-type="ref"}, [^45^](#b45){ref-type="ref"} We suggest that an important feature of the 2009 influenza A (H1N1) pandemic, which may have contributed substantially to the diminished severity of this pandemic, is the circulation of sH1N1 as a sometime‐dominant seasonal influenza strain for some 23 years prior to the emergence of nH1N1. Although extensive cross‐protection against nH1N1 in younger individuals would not have been expected based on documented sero‐epidemiological profiles,[^27^](#b27){ref-type="ref"}, [^28^](#b28){ref-type="ref"} we demonstrate that atypical features of this pandemic are compatible with a major (and under‐appreciated) role for pre‐existing T‐cell immunity against influenza nH1N1 infection.[^10^](#b10){ref-type="ref"}, [^11^](#b11){ref-type="ref"}

To elucidate whether there could be some level of cross‐reactivity from CD4+ T‐cells between sH1N1 strains and nH1N1, we conducted an epitope prediction‐based analysis. Our results show the existence of a high level of CD4+ T‐cell cross‐reactivity that could influence disease outcomes. We failed to identify T‐cell cross‐reactivity between H3N2 and nH1N1 subtypes, which may be because of distinctive surface antigens.[^46^](#b46){ref-type="ref"} Consistent with previous work, our analysis indicates that minimal CD4+ T‐cell epitopes (i.e. core region) from nH1N1 HA1 and HA2 exhibit overlapping epitopes with CD8+ T‐cell.[^47^](#b47){ref-type="ref"}, [^48^](#b48){ref-type="ref"} The generation of classical CD8+ effector CTL responses generally require *in vivo* priming, either through natural infection or vaccination,[^47^](#b47){ref-type="ref"} involving licensing of antigen‐presenting cells (APC) because of APC and CD4+ T helper cell interaction in the context of MHC II. Such APC licensing is crucial for efficient induction of CTL responses.[^49^](#b49){ref-type="ref"}, [^50^](#b50){ref-type="ref"} Our study identifies epitopes that are conserved among different influenza strains and also represents overlapping CD4+ and CD8+ T‐cell epitopes, which represent attractive novel candidates for the development of T‐cell‐based vaccines.

Human leukocyte antigen (HLA) is an important genetic regulator of adaptive immunity, especially for T‐cell immune responses. In the current study, all the predicted CD4+ T‐cell HA‐epitopes are restricted to HLA‐DRB1\*0101, and some of these epitopes are promiscuous with other sub‐alleles of DRB1, \*0401, \*0404, \*0701, and \*1501. The promiscuity between these epitopes suggests the possibility of acquired cross‐immune responses to novel influenza infections from earlier exposures. Understanding the association between the immune responses to natural infection and HLA polymorphic genes is therefore crucial for the development of universal influenza vaccines based on the highly conserved and strain cross‐reactive epitopes. Earlier work on seasonal influenza A viruses has identified the importance of class II HLA‐DR alleles and shown HLA‐DR3 and DR4 to be associated with reduced elicitation of vaccine‐induced immunity in patients with type I diabetes.[^51^](#b51){ref-type="ref"} An increased frequency of DRB1\*0701 has been shown among non‐responders to trivalent subunit vaccines; however, these individuals were found to recognize identical CD4+ T‐cell HA‐epitopes of influenza viruses.[^33^](#b33){ref-type="ref"} These observations warrant further investigation into the role of HLA polymorphisms and immune responses to infection, vaccination, and autoimmune diseases.

Our conclusions drawn from a bioinformatics study on HA protein corroborate a recent experimental analysis of cross‐reactive CD4 T‐cell memory response against nH1N1 conferred by prior exposure to sH1N1 viruses.[^52^](#b52){ref-type="ref"} The immunodominant HA‐epitopes, HA~316,~ (TGLRNIPSIQSRGLFGAIA), HA~381~ (SVIEKMNTQFTAVGK), and HA~424~ (ELLVLLENERTLDYH) (see Table S2), are shown to be highly conserved between sH1N1 and nH1N1.[^52^](#b52){ref-type="ref"} In structural perspective, these conserved epitopes are found in the HA2 segment of HA protein, which is known to be a stalk region.[^53^](#b53){ref-type="ref"}, [^54^](#b54){ref-type="ref"} In line with previous work,[^55^](#b55){ref-type="ref"} we have shown that there may be potential CD4 T‐cell help for the B cells targeting the HA2 region, where the majority of conserved epitopes (66·6%) are unveiled and seems to be in the stalk of HA structure found in our analysis ([Table 4](#t4){ref-type="table-wrap"}).

Several factors may influence the degree of immunological cross‐reactivity, including immunological history and frequency of exposure to variants of a specific viral strain,[^56^](#b56){ref-type="ref"}, [^57^](#b57){ref-type="ref"}, [^58^](#b58){ref-type="ref"} and therefore conservancy of epitopes does not necessarily correspond to cross‐reactivity. Using a highly efficient epitope prediction tool (NETMHCIIPan[^66^](#b66){ref-type="ref"}) and considering all the HA protein sequences of H3N2, sH1N1, and nH1N1 strains available in the National Center for Biotechnology Information (NCBI) since their emergence, we have revised prior estimates of 41% CD4+ T‐cell cross‐reactivity[^11^](#b11){ref-type="ref"} upwards by a large margin to 52%. Our analysis included nH1N1 HA protein sequences from April to August 2009 submissions from Influenza Virus Sequence Database and is limited to some degree by the lack of entries for more recent strains in the database.

A further practical implication of these findings relates to the urgent public health response to newly emerged influenza strains with epidemic or pandemic potential in humans: in this context population immunity is generally assayed via sero‐epidemiological studies.[^25^](#b25){ref-type="ref"}, [^56^](#b56){ref-type="ref"} However, as our analysis demonstrates, estimating the prevalence of neutralizing antibody may not be sufficient for characterizing the epidemiology of the disease or accurately projecting the future course of epidemics. Although evaluation of the prevalence of pre‐existing cellular immune responses to a novel influenza virus is likely to be more time‐consuming, complex, and expensive than traditional sero‐epidemiological studies, the widespread availability of commercial cytokine elaboration assays suggests that this may not be an unattainable goal in relatively resource‐rich settings, and gathering information on cellular responses may allow for a more nuanced and efficient response to future epidemics and pandemics. It is notable that the behavior of several other respiratory pathogens (including mumps and pertussis) has proven difficult to predict using models based on sero‐epidemiological data alone, suggesting a future role for the integration of information on cellular immune responses into such models.[^57^](#b57){ref-type="ref"}

Our study has several limitations. Most notably, because of the tendency of influenza A viruses toward antigenic drift via high mutation rates for surface proteins,[^59^](#b59){ref-type="ref"} further analysis of the sequences past August 2009 would be required to determine the conservancy of epitopes. To calculate the conservancy ratio of available sequences, we considered only epitopes that are 100% conserved. While some of the predicted epitopes in our analysis were in agreement with previous experimental studies,[^11^](#b11){ref-type="ref"}, [^25^](#b25){ref-type="ref"} new cross‐reactive T‐cell epitopes were identified -- in particular CD4+ and CD8+ T‐cell overlapping epitopes -- and therefore further investigation should be conducted for the quantification of T‐cell responses. Considering the role of MHC class II in HA epitope selection,[^25^](#b25){ref-type="ref"} we analyzed all the HA protein sequences of seasonal H1N1, H3N2, and the novel H1N1 available at the NCBI influenza genome databank ([Figure 1](#f1){ref-type="fig"}). While the analysis aimed at determining T‐cell cross‐reactivity, we note that the MHC presentation is not necessarily reflective of T‐cell response, and therefore proliferation assays are needed to confirm the T‐cell response to these predicted epitopes. Nevertheless, overlap of the predicted epitopes with experimental work[^25^](#b25){ref-type="ref"} provides a good degree of validation and confidence to derive the implications of the cross‐reactivity, which highlights the importance of pre‐existing memory T‐cell responses against an emerging influenza virus.

Although pre‐existing immunity is a self‐protection mechanism, its effects often extend well beyond the individuals, by influencing the transmission dynamics of the pathogen in the population as a whole. These effects may appear as a prolonged incubation period,[^5^](#b5){ref-type="ref"} reduced severity of the disease,[^4^](#b4){ref-type="ref"}, [^26^](#b26){ref-type="ref"} and reduced infectiousness.[^5^](#b5){ref-type="ref"}, [^7^](#b7){ref-type="ref"} Further evaluation of cross‐reactive T‐cell immunity and its implications for epidemic dynamics at the population level remains an important task for modeling and simulations of disease spread and control. In this context, previous studies involving within‐host models of viral‐immune dynamics have demonstrated that pre‐existing cellular immunity can also interfere with the evolutionary responses of influenza viruses and prevent *in vivo* emergence of drug resistance and its spread between individuals.[^60^](#b60){ref-type="ref"}, [^61^](#b61){ref-type="ref"} We hope that this study, combined with the ongoing research on real‐time monitoring of the 2009 influenza pandemic, will guide future research and help foster the design of scientific frameworks that strengthen links between viral‐immune dynamics at the individual level and disease transmission and control at the population level. Such an integrative and trans‐disciplinary approach will foster understanding of influenza virology, immunology, and epidemiology and consequently will improve the ability to respond to and control this still‐deadly disease.

Materials and methods {#ss6}
=====================

Sequence analysis of influenza A viruses {#ss7}
----------------------------------------

A total of 217, 532, and 56 HA protein sequences of sH1N1, seasonal H3N2, and nH1N1 strains, respectively, from years 1968 to 2009 were obtained from the Influenza Virus Resource at the NCBI.[^62^](#b62){ref-type="ref"} Identical sequences were deleted by using the option 'collapse identical sequences' (Sequence accession numbers were included in supplementary information S7). We employed BioEdit, a biological sequence alignment editor,[^63^](#b63){ref-type="ref"} for the analysis of HA sequences. Multiple sequence alignments were performed using ClustalW[^64^](#b64){ref-type="ref"} with default parameters offered by BioEdit as an external program. To predict the strongly conserved common epitopes against MHC II alleles, the following sequences, A/New Jersey/AF09/2008 for sH1N1; A/Brisbane/59/2007 for seasonal H1N1 vaccine (vH1N1); and A/California/04/2009 for nH1N1 were used. These epitope numbers were used to calculate the fraction of CD4+ T‐cell cross‐reactivity.

Major Histocompatibility Complex (MHC) class II allele's selection {#ss8}
------------------------------------------------------------------

For the selection of MHC alleles, we considered a previous investigation into the human CD4+ T‐cell repertoire response toward influenza A virus HA gene following natural infection.[^25^](#b25){ref-type="ref"} The subjects utilized were 12 unrelated healthy adult donors (ages 21--55 years) with a history of influenza (A/Beijing/32/92) infection without vaccination, and the control group consisted of 6 healthy individuals (ages 28--42 years) with no history of influenza‐like illness during the preceding 4 years (Table 1 in[^25^](#b25){ref-type="ref"}). Donors who expressed HLA‐DRB1 and HLA‐DQB1 MHC alleles with a recent history of influenza infection induced strong cell‐mediated responses to the peptide pools derived from HA.

Predicting binding affinities of HLA‐DR alleles and epitopes of HA gene {#ss9}
-----------------------------------------------------------------------

### Selection of peptide binding prediction tool {#ss10}

Major Histocompatibility Complex‐II peptide binding prediction servers have been evaluated[^65^](#b65){ref-type="ref"} by measuring the prediction accuracy in terms of the area under the receiver operating characteristic curve (A~ROC~), NETMHCIIPAN[^66^](#b66){ref-type="ref"} has been identified as best predictor (A~ROC~ \> 0·9), and closely followed by PROPRED,[^67^](#b67){ref-type="ref"} IEDB,[^68^](#b68){ref-type="ref"} and MULTIPRED.[^69^](#b69){ref-type="ref"} Hence, NETMHCIIPAN was chosen to calculate the binding affinities of peptide‐HLA‐DR alleles and to identify the optimal peptides.

### HA gene comparative analysis of sH1N1 and nH1N1 against HLA‐DR alleles {#ss11}

FASTA format of HA protein sequences of sH1N1, vH1N1, and nH1N1 were individually analyzed for binding affinities against the selected alleles DRB1\*0101, DRB1\*0301, DRB1\*0401, DRB1\*0701, DRB1\*0801, DRB1\*1101, DRB1\*1301, and DRB1\*1501 in the NETMHCIIPAN online server. The following information was provided by the server for each peptide: position, core region, log‐transformed binding value (1−log50k), and binding affinity (n[m]{.smallcaps}) of strong (threshold 50·000) and weak (threshold 500·00) peptides.

Epitope conservancy analysis {#ss12}
----------------------------

For the initial analysis to predict the conserved epitopes for HLA‐DR alleles, only recent strains from sH1N1 (2008), vH1N1 (2007), and nH1N1 (2009) were used. Predicted epitopes were mapped among the list of sequences (supplementary information S7) to elucidate the epitope conservancy over the years 1968--2009. Epitope Conservancy Tool[^70^](#b70){ref-type="ref"} was employed to investigate the conservancy across the seasonal and novel HA proteins. Statistical analysis was performed using GraphPad Prism 5.0 to determine the correlation between conservancy of epitopes within the groups: sH1N1 versus nH1N1, H3N2 versus nH1N1, and sH1N1 versus H3N2.
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